BTIG analyst Mark Massaro raised the firm’s price target on Exact Sciences to $82 from $70 and keeps a Buy rating on the shares. The firm noted that the share are up about 5% today following the company’s blood-based CRC test readout from a partial case control study read out. There is some risk that degradation could exceed expectations, ut for now the firm thins most are expecting data degradation of 5-8 points on overall sensitivity in the pivotal readout, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Canaccord sees colon blood test as attractive revenue stream for Exact
- Exact Sciences announces data for CRC screening test
- Exact Sciences price target raised to $85 from $75 at Piper Sandler
- Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI
- Foot Locker trips after earnings, Kohl’s posts Q2 beat: Morning Buzz